Detection of Beta-Glucan Contamination in Nanotechnology-Based Formulations

Barry W. Neun, Edward Cedrone, Timothy M. Potter, Rachael M. Crist and Marina A. Dobrovolskaia *

Nanotechnology Characterization Lab, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research Sponsored by the National Cancer Institute, Frederick, MD 21702, USA; neunb@mail.nih.gov (B.W.N.); edward.cedrone@nih.gov (E.C.); pottert@mail.nih.gov (T.M.P.); cristr@mail.nih.gov (R.M.C.)
* Correspondence: marina@mail.nih.gov; Tel.: +001-301-228-4935
Academic Editors: Kirill A. Afonin and Derek J. McPhee

Received: 8 July 2020; Accepted: 23 July 2020; Published: 24 July 2020

Abstract: Understanding the potential contamination of pharmaceutical products with innate immunity modulating impurities (IIMIs) is essential for establishing their safety profiles. IIMIs are a large family of molecules with diverse compositions and structures that contribute to the immune-mediated adverse effects (IMAE) of drug products. Pyrogenicity (the ability to induce fever) and activation of innate immune responses underlying both acute toxicities (e.g., anaphylactoid reactions or pseudoallergy, cytokine storm) and long-term effects (e.g., immunogenicity) are among the IMAE commonly related to IIMI contamination. Endotoxins of gram-negative bacteria are the best-studied IIMIs in that both methodologies for and pitfalls in their detection and quantification are well established. Additionally, regulatory guidance documents and research papers from laboratories worldwide are available on endotoxins. However, less information is currently known about other IIMIs. Herein, we focus on one such IIMI, namely, beta-glucans, and review literature and discuss the experience of the Nanotechnology Characterization Lab (NCL) with the detection of beta-glucans in nanotechnology-based drug products.

Keywords: immunology; beta-glucans; contamination; drug safety; nanoparticles; sterility; endotoxin; glucatell; fungitell; factor-C-depleted Limulus amoebocyte lysate assay

1. Introduction

Concerns about and methodologies for the detection of innate immunity modulating impurities (IIMIs) in pharmaceutical products have a long history [1]. Over the past couple of decades, significant progress has been made in detecting and quantifying product contamination with bacterial endotoxins; several in vitro and in vivo methods have been developed, extensively studied, reviewed in the literature [2–7], and addressed in guidance for industry documents by regulatory authorities worldwide [8–10]. The issue of potential product contamination with IIMIs received more attention when biopharmaceuticals (e.g., recombinant proteins, antibodies, and peptides) entered the generics phase [1,11]. The determination of bioequivalence for generic biotechnology products to their respective reference listed drugs (RLDs), among other tests, requires an understanding of the products’ immunogenicity, which in turn may be influenced by IIMIs. Therefore, accentuating the importance of detection of these impurities in drug products and understanding how their presence affects products’ safety profiles have become important issues for drug development [12,13].

Nanotechnology therapeutics include a variety of chemically distinct platforms, and usually are complex in that they may contain small molecules, nucleic acids, peptides, proteins, or antibodies for...
targeting, as active pharmaceutical ingredients (API) or both (Figure 1). Depending on the sources of individual components and nuances of manufacturing, nanotechnology formulations may become contaminated with various IIMIs (Figure 1). However, neither the methodology for detection of IIMIs nor recognition of the potential importance of this issue for the field of nanomedicine is as well established as the current state of knowledge about endotoxins in nanoformulations. Herein, we focus on one such IIMI, namely, beta-glucans, and review the current literature on the topic, and describe the experience of the Nanotechnology Characterization Laboratory (NCL; https://ncl.cancer.gov) with the detection of beta-glucans in nanotechnology-based drug products.

**Figure 1. The complex nature of nanotechnology-based therapeutics.** Nanomaterials can have a diverse chemical compositions and a broad range of physicochemical properties (e.g., size, charge, and surface functionalization), and are used for delivery of a variety of therapeutic cargoes (e.g., proteins, peptides, antibodies, and aptamers). The diverse nature of these materials, coupled with complex manufacturing procedures, makes nanomaterials prone to contamination with microbial components (e.g., endotoxin, beta-glucans, and flagellin) that act as innate immunity modulating impurities, thereby confounding the results of both efficacy and safety studies.

### 2. Overview of Beta-Glucans

Beta-glucans are a family of polysaccharides with heterogeneous chemical structures (Figure 2) that are present in the cell walls of certain microorganisms (e.g., some bacteria, yeast, and fungi), algae, mushrooms and plants [14–17]. Several types of beta-glucan molecules have been described in the literature based on the positioning of the β-glycosidic bond(s)—β-(1,3); β-(1,3), β-(1,4); β-(1,3), β-(1,2), β-(1,4), β-(1,6); β-(1,2) and β-(1,3), β-(1,6)—connecting individual monomer units of D-glucose into a polymer (Figure 2A) [18]. The β-glucan polymers can take a variety of forms. Linear (short and long), branched (branch-on-branch and side-chain branched), and cyclic molecules of beta-glucans have all been identified, and can utilize a single glycosidic linkage (e.g., the linear β-(1,3)-D-glucan polymer) or multiple glycosidic linkages (e.g., the branched β-(1,3), β-(1,6)-D-glucan polymer) (Figure 2B). Alpha-glucans, which are polysaccharides of alpha-D-glucose rather than beta-D-glucose, are also commonly found in microorganisms and plants. However, α-glucans are much less pro-inflammatory as compared to β-glucans and at the moment are not considered a significant IIMI risk.
Figure 2. Chemical structures of beta-glucans. (A). Beta-glucans are named according to the positioning of the glycosidic linkage. The nomenclature specifies which carbons of the glucose rings are conjugated to form the polymeric structure, with carbon 1 always representing the anomeric carbon. For example, a β-(1,3) linkage conjugates the anomeric carbon of one glucose moiety to carbon 3 of another glucose moiety. β-(1,2), β-(1,3), β-(1,4), and β-(1,6) are all common linkages for beta-glucan molecules. (B). Beta-glucans can be linear (short and long), branched (branch-on-branch and side-chain branched) and cyclic, and can constitute polymers that utilize a single linkage positioning (e.g., β-(1,3)) or multiple linkage positionings (e.g., β-(1,3), β-(1,4)). Structures of common β-glucans within each class are given.

The structure (i.e., linear vs. branched vs. cyclic), conformation (i.e., triple helix vs. single helix vs. random coil), degree of branching, linkage (i.e., β-(1,3) vs. β-(1,4), etc.), and molecular weight of β-glucans all play important roles in the overall properties of the polymers, including physical aspects such as solubility, viscosity, and crystallinity, and biological aspects stemming from physiological responses to the polymers [14,16,18]. Perhaps most remarkable is the ability to activate innate immune responses depending on these physicochemical properties [14,16,18,19]. For example, a study by Noss et al. compared twelve beta-glucans with various types of β-glycosidic bonds (i.e., β-(1,3) vs. β-(1,4) vs. β-(1,6) vs. β-(1,3) vs. β-(1,4) vs. β-(1,6)) and obtained from different sources (i.e., plant, yeast, fungi, bacteria, algae, and lichen) by using in vitro human whole blood assays to assess cytokine responses [20]. This study discovered both quantitative and qualitative differences in the cytokine profile induced by the tested beta-glucans. For example, glucans from lichens containing β-(1,4) and β-(1,6) linkages were more potent inducers of pro-inflammatory cytokines than beta-glucans with other structures or similar structures but obtained from fungi or bacteria [20]. Pro-inflammatory cytokines TNFα, IL-1β, IL-6, and IL-8 were reported as biomarkers of the beta-glucan-mediated pro-inflammatory response in human blood [20]. This observation is consistent with another study that also observed TNFα, IL-6, and IL-8 in whole blood cultures of healthy donors treated in vitro with yeast and synthetic β-(1,3)-glucans [21]. Interestingly, this study also demonstrated that linear fragments of beta-glucans were more potent at inducing Th1 responses in human blood cells in vitro than full-size molecules [21]. Another interesting observation is that synthetic beta-glucans were weaker immunostimulants than their naturally derived counterparts [21]. Even though the authors conducted experiments to rule out the potential contribution of endotoxin contamination to the cytokine response [21], it is not improbable that other undetected IIMIs present in the naturally-derived beta glucans contributed to their higher potency. Other examples demonstrating the structure activity relationships of beta glucans in different species both in vitro and in vivo are summarized in Table 1.
Table 1. Immunological properties of glucans from various sources. The table summarizes select examples from published studies demonstrating various types of immune responses to beta-glucans. * Whenever available, a common name is provided in parentheses. ROS = reactive oxygen species; HSP = heat shock proteins; Gm− = Gram-negative; N.S. = not specified; i.m. = intra-muscular; s.c. = subcutaneous.

| Type of β-glucan Molecule * | Source | On Beads (B), Particulate (P) or Soluble (S) | Immunological Response | In Vitro or In Vivo | Reference |
|-----------------------------|--------|---------------------------------------------|------------------------|---------------------|-----------|
| β-(1,3)-D-glucan            | N.S.   | N.S.                                        | IL-6, TNFα, IL-1RA production by human monocytes | In vitro | [22] |
| β-(1,6)-D-glucan (pustulan) | Yeast  | B                                           | Activation of phagocytic function, production of ROS and high levels of HSP by human neutrophils | In vitro | [23] |
| β-(1,3)-D-glucan (laminarin)| Yeast  | B                                           | Low levels of HSP production by human neutrophils | In vitro | [23] |
| β-(1,4)-D-glucan            | Yeast  | B                                           | Not immunostimulatory in human neutrophils as indicated by ROS and HSP levels | In vitro | [23] |
| β-(1,3)-D-glucan with some β-(1,6) branching at 3:1 ratio (laminarin) | Algae  | S                                           | Lymphocyte proliferation in porcine PBMC | In vitro | [24] |
| β-(1,3)-D-glucan with some β-(1,6) branching at 6:1 ratio (scleroglucan) | Fungi  | S                                           | Lymphocyte proliferation; TNFα and IL-10 secretion by porcine PBMC | In vitro | [24] |
| β-(1,3)-D-glucan unbranched (curdlan) | Gm-Bacteria | P                                          | Lymphocyte proliferation; ROS production by monocytes and neutrophils; TNFα and IL-10 secretion by PBMC of porcine origin | In vitro | [24] |
| β-(1,3)-D-glucan unbranched | Algae  | P                                           | Lymphocyte proliferation; ROS production by monocytes and neutrophils; TNFα and IL-10 secretion by PBMC of porcine origin | In vitro | [24] |
| β-(1,3)-D-glucan with some β-(1,6) branching at 30:1 ratio | Yeast | P | Lymphocyte proliferation; ROS production by monocytes and neutrophils; TNFα and IL-10 secretion by PBMC of porcine origin | In vitro [24] |
|---|---|---|---|---|
| β-(1,3), β-(1,6) branched with 10:1 or 20:1 ratio (macrogard) | Yeast | P | Lymphocyte proliferation; ROS production by monocytes and neutrophils; TNFα and IL-10 secretion by PBMC of porcine origin | In vitro [24] |
| β-(1,3), β-(1,6)-D-glucan uniformly branched (Zymozan) | Yeast | P | Lymphocyte proliferation; ROS production by monocytes and neutrophils; TNFα and IL-10 secretion by PBMC of porcine origin | In vitro [24] |
| β-(1,3)-D-glucan unbranched (curdlan) | Gm- Bacteria | P | Maturation of human monocyte-derived DC; Th17 differentiation and stimulation of mixed leukocyte reaction | In vitro [25] |
| β-(1,3)-D-glucan unbranched (curdlan) | Gm- Bacteria | P | Secretion of IL-1β, IL-6, IL-23, IL-10, and TNFα by human PBMC | In vitro [26] |
| β-(1,3), β-(1,6)-D-glucan uniformly branched (Zymozan) | Yeast | P | Secretion of IL-1β, IL-6, IL-23, IL-10, and TNFα by human PBMC | In vitro [26] |
| β-(1,3)-D-glucan | Yeast | P | Antigen-specific IgG2c and potent CD4+ T-cell activation in mice after s.c. injection | In vivo [27] |
| β-(1,3), β-(1,6)-D-glucan uniformly branched (Zymozan) | Yeast | P | Complement activation; foot swelling; CTL activation; antigen-specific IgG2a antibody response and potent CD4+ Th1 response in mice after i.m. injection | In vivo [28] |
| Molecule | Source | Effect | Reference |
|----------|--------|--------|-----------|
| β-(1,3)-D-glucan unbranched (curdlan) | N.S. | Elevated IL-8 levels in nasal secretions of human subjects exposed via the inhalation route | In vivo [29] |
| β-(1,3)-D-glucan | Yeast | Induction of IFNγ responses in mice after oral administration | In vivo [30] |
| β-(1,6)-backbone and β-(1-3)-side branches | Mushrooms | Elevation of L-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-17, G-CSF, GM-CSF, IFN-γ, MCP-1, MIP-1β and TNF-α levels after oral administration in healthy human donors, and in human blood cultures | In vivo and in vitro [31] |
β-(1,3)-D-Glucans are not as immunologically potent as bacterial endotoxins but do possess immunomodulatory properties. For example, a study comparing twelve beta-glucans from various sources and with different types of glycosidic bonds reported pro-inflammatory responses to these molecules at concentrations ranging from 25 to 250 µg/mL. In contrast, the same study observed a pro-inflammatory response to bacterial lipopolysaccharides (LPS) at picogram/mL concentrations [20]. Moreover, beta-glucans were shown to exaggerate endotoxin-mediated toxicities and synergize with other immunologically-active impurities introduced into pharmaceutical products during manufacturing, thereby contributing to the adverse immune effects [32–34].

Pattern recognition receptors involved in the inflammatory signaling triggered by beta-glucans include Toll-like receptors (TLR2, TLR4, and TLR6) [35–37], dectin-1 [38–40], CD36 [41], scavenger receptor CD5 [42], complement receptor CR3 [43–45], and lactosylceramide [17]. Activation of these receptors by beta-glucan molecules results in activation of various signaling pathways, including but not limited to those triggering the activation of Src, Syk, MAP, PI3K, Akt, PKC, and IκB kinases, and key transcription factors such as NFκB, AP-1, and NFAT [46]. These receptors are differentially expressed on a wide variety of cells involved in innate immunity, such as monocytes, neutrophils, natural killer cells, granulocytes, and macrophages. Cooperation between these cells provides a coordinated response to beta-glucans.

While the exact mechanism of immunomodulation by beta-glucans is not understood, activation of the expression of TLR10 on immune cells is thought to contribute to their mechanism of action [22]. TLR10 is a member of TLR family that does not have a natural ligand but can form heterodimers with TLR1 and TLR6; it is thought to support epigenetic and metabolic reprogramming of innate immune cells in response to certain agonists present in vaccines or provided by infections and confers the enhanced response of these cells to the secondary stimulation, thereby contributing to the immunomodulation or so-called “trained” immunity [22,47].

The research on beta-glucans is of interest to pharmaceutical scientists for three reasons. First, β-(1,3)-D-glucans from dietary sources are found at low levels (<60 pg/mL) in the blood of healthy humans, whereas in patients with invasive fungal infections, these levels increase to ≥ 80 pg/mL [15,48–51]. Therefore, assessing the levels of beta-glucans in peripheral blood can serve as a diagnostic procedure for fungal infections. Second, beta-glucans are considered active ingredients in treatments aimed at improving immunity in a variety of disorders, including cancer [52]. Various forms of oral formulations are promoted worldwide as over-the-counter remedies, and some formulations are being also considered for either systemic or oral administration and undergoing clinical evaluation [53–60]. Third, β-(1,3)-D-glucans may become undesirable contaminants in pharmaceutical products, where they are inadvertently introduced during manufacturing either through certain types of personal protective equipment (PPE) suits and other cellulose-based materials (e.g., cellulose-acetate filters, cotton plugs) used in manufacturing facilities or from fungal contamination of starting materials (e.g., sucrose and sucrose-containing buffers), tools, and equipment [32,61] (Table 2). The most common sources of β-(1,3)-D-glucan contamination in pharmaceuticals are from fungi Candida and Aspergillus [48]. Moreover, the FDA immunogenicity guidance for industry suggests minimizing the levels of β-(1,3)-D-glucans in therapeutic protein formulations to decrease the immunogenicity risks of these products [62].

| Source of Contamination | Solution |
|-------------------------|----------|
| Cellulose-fiber containing PPE suits | Use PPE suits made of other polymers (e.g., high-density polyethylene fibers like those in DuPont™ Tyvek® suits) |
| Cotton-containing plugs in serological pipettes and tips | Use pipettes and tips with synthetic polymer-based aerosol control barriers |

Table 2. Common sources of beta-glucan contamination in pharmaceutical products and solutions for avoiding contamination. Assays, such as Glucatell, could be used by individual laboratories to validate materials, procedures, and environments to minimize contamination. PPE = personal protective equipment.
Cellulose-based filters
Replace cellulose-acetate filters with other filter types; prime the filter to reduce levels of eluted glucans (the number of priming cycles may vary for different filtration units and should be determined empirically).

Sucrose and sucrose-containing buffers
Screen multiple batches and select that with minimal to no contamination;
Establish a reliable supply chain

Starting materials (especially of plant origin)
Screen all starting materials and use those free of contamination;
Establish a reliable supply chain

Water
Screen water and use batches free of contamination;
Establish a reliable water source

Fungal contamination in the laboratory environment
Perform regular microbiological monitoring of the laboratory equipment and environment to detect and eliminate fungal contamination

Since many nanotechnology platforms are not immunologically inert, understanding the presence of immunologically reactive contaminants besides endotoxin is becoming essential step in understanding the safety margins for formulations containing such materials [63]. For example, immune-mediated adverse reactions, including but not limited to infusion reactions (IRs) that occur within the first minutes to hours of systemically administered nanomedicines, are of paramount importance to patient safety. Anaphylactoid reactions, pseudoallergy, or complement-activation mediated pseudoallergy (CARPA) are common types of IRs to nanotechnology-formulated drug products. At the moment, the majority of data link nanomedicine-triggered IRs to the physicochemical properties of nanomaterials [64]. However, an IR induction by infused beta-glucans has also been reported in the literature [65,66]. Therefore, understanding the role of nanoparticle contamination with beta-glucans in IRs to nanomedicines is very important and may help to reduce both the incidence and severity of IRs. Moreover, understanding beta-glucan contamination of nanomedicines becomes particularly essential when such formulations are used for immunotherapy involving the intentional application of immune checkpoint inhibitors to enhance the immune response.

3. Detection of Beta-Glucans

Unlike bacterial endotoxins, the levels of β-(1,3)-D-glucan contaminants in pharmaceutical products are currently not regulated. There is no compendial standard for their detection or harmonized approach to acceptable levels. Nevertheless, there is a growing trend in the industry and among regulatory authorities worldwide to detect and quantify β-(1,3)-D-glucans, and to understand their safe levels [32–34].

Similarly to endotoxin, beta-glucans activate a cascade of proteins present in the lysate derived from amoebocytes of the horseshoe crab *Limulus polyphemus* and widely used in the so-called Limulus amoebocyte lysate (LAL) assay [67] (Figure 3). The raw lysate obtained from amoebocytes contains two proteins that trigger the activation of the proteolytic cascade in response to endotoxin and beta-glucans; they are factor C and factor G, respectively [67]. When the LAL assay is conducted using this lysate, the presence of factor G creates a false-positive interference of beta-glucans during endotoxin detection [68]. To overcome such interference, the assay is either modified to include glucan-blocking reagents or performed using recombinant factor C [2,69,70]. Likewise, when factor C is depleted from the lysate, the remaining factor G initiates a proteolytic cascade in response to the presence of beta-glucans [71] (Figure 3).
Figure 3. Proteins and triggering factors of the Limulus amoebocyte lysate (LAL) Assay. Proteins in the amoebocyte lysate of the horseshoe crab *Limulus Polyphemus* are zymogens organized in a sequential enzymatic cascade. These proteins are shown in the figure as green ovals. After the activation by either a triggering factor or preceding protein, the active form of a protein forms and is shown as a yellow rectangle; “a” at the beginning of the protein name refers to its activated state. The LAL assay can detect both endotoxins and beta-glucans. However, with slight modifications shown in the figure, the LAL may become specific to either endotoxin (left flow diagram shown in blue) or beta-glucan (right flow diagram shown in purple). These modifications are used in commercial kits (e.g., Fungitell and Glucatell) [48,72], and other commercially available reagents (e.g., Glucashield) [73].

While the LAL assay is widely used for the detection and quantification of endotoxin contamination, its factor-C-free version, available from various manufacturers and under different tradenames, including Fungitell, Glucatell, Endosafe Nexgen-PTS, and Toxinometer MT-6500, is used to detect beta-glucans (Table 3). The Glucatell assay is used for research purposes [72], whereas the Fungitell assay is approved by the US FDA for the diagnosis of fungal infections [48]. The Fungitell assay has also been available in Europe since 2008. Toxinometer MT-6500 is another diagnostic assay that is available in the US and Asia [74]. Additional methods have also been described; they include ELISA [75] and chemical hydrolysis and enzymatic degradation-based methods [76–78] (Table 3). Modified LAL and ELISA assays provide higher sensitivity and are used for the detection of betaglucans in pharmaceuticals, and in the case of diagnostic assays, in patients’ sera or plasma. The methods involving acid hydrolysis and enzymatic degradation are widely used in the food industry to quantify beta-glucans in dietary products. Additionally, methods for isolation of beta-glucans and characterization of their physicochemical properties are also available and reviewed elsewhere [79].
**Table 3.** Assays for detection of beta-glucans in biological matrices and test-materials. LAL = Limulus amoebocyte lysate assay.

| Assay Type/Name                      | Manufacturer                | Detection Range | Diagnostic (D), R&D (R), or Food (F) | Type of Assay                                                                 | Reference |
|--------------------------------------|-----------------------------|-----------------|--------------------------------------|--------------------------------------------------------------------------------|-----------|
| Biochemical/Fungitell                | Associates of Cape Cod      | 31.25–500 pg/mL | D                                    | Modified LAL assay based on the measurement of optical density at 405 nm        | [48]      |
| Biochemical/Glucate                   | Associates of Cape Cod      | 5–40 pg/mL      | R                                    | Modified LAL assay based on the measurement of optical density 405 nm (kinetic) or 540 nm (end-point) | [72]      |
| ELISA/QuickDetect™                   | Biovision                   | 0.8–50 pg/mL    | D&R                                  | Sandwich ELISA detecting absorbance at 450 nm                                   | [75]      |
| Biochemical/Toxinometer MT-6500      | Fuji Film                   | 6–600 pg/mL     | D                                    | Modified turbidimetic LAL assay                                               | [74]      |
| Biochemical/Endosafe Nexgen-PTS      | Charles River               | 10–1000 pg/mL   | R                                    | Modified LAL, cartridge-based dedicated spectrophotometric assay               | [80]      |
| Chemical&Enzymatic/β-glucan yeast & mushroom | Megazyme                     | 1 g/100 g       | F                                    | Acid-based hydrolysis of beta-glucans, followed by enzymatic degradation and measurement of absorbance at 510 nm | [76]      |
| Enzymatic/yeast β-glucan             | Megazyme                    | 1 g/100 g       | F                                    | Enzymatic degradation assay measuring absorbance at 510 nm                     | [77]      |
| Enzymatic/ β-glucan (mixed linkage)  | Megazyme                    | 0.5 g/100 g     | F                                    | Enzymatic degradation assay measuring absorbance at 510 nm                     | [78]      |
Studies regarding the utility of these assays for the analysis of beta-glucan contamination in engineered nanomaterials are scarce [81]. Table 4 summarizes the experience of our laboratory (https://ncl.cancer.gov) with applying the commercial Glucatell kit to screen commercial and preclinical, research-grade nanoparticle formulations for the presence of beta-glucans. The detailed experimental procedure, materials and supplies, reagent volumes, and assay incubation temperature and times are described in NCL protocol STE-4, available for download online (https://ncl.cancer.gov/sites/default/files/protocols/NCL_Method_STE-4.pdf). In our studies, the levels of beta-glucans in tested formulations varied widely from undetectable (<2.5 pg/mg) to 181,000 pg/mg of the API (Table 4). Even though some of these levels may appear high (e.g., 181,000 pg/mg), when these nanomaterials are dosed at their intended therapeutic doses, the amounts of injected beta-glucans do not exceed levels detected in the blood of healthy individuals stemming from dietary sources (see approach 4 below and reference [81] for details). Therefore, it is important to consider the data generated from beta-glucan quantification assays in the context of the dose of the nanoparticle-based product. The results obtained in our laboratory (Table 4) also demonstrate that, similarly to the experience with LAL assays [2,68–70,81,82], nanoparticles may interfere with beta-glucan detection and a valid response is not always observed at the lowest tested dilution. Therefore, inhibition/enhancement controls are important to verify the validity of the test-results.

Table 4. Levels of beta-glucans in various formulations. Three dilutions (5, 50, and 500-fold) of the stock nanomaterial were prepared in pyrogen-free water for all formulations and tested with the commercial factor-C-depleted LAL assay (Glucatell®) using the procedure detailed in https://ncl.cancer.gov/sites/default/files/protocols/NCL_Method_STE-4.pdf. The results were normalized to provide beta-glucan levels in picograms per milligram of active pharmaceutical ingredient (API). The spike recovery and inhibition/enhancement control (IEC) requirements for the LAL assay were used to evaluate the performance of the Glucatell assay. The IECs were prepared by spiking a known concentration of beta-glucan standard into the test sample at each dilution. A recovery of 50–200% was considered acceptable, whereas recovery outside of this range suggested nanoparticle interference; consequently, the data from dilutions demonstrating unacceptable spike recovery were considered invalid and excluded from the analysis. The data presented are from the lowest dilution that did not interfere with the assay. BLOQ = below the assay lower limit of quantification (undetectable); SPIO = superparamagnetic iron oxide; PEG = poly(ethylene glycol).

| Platform                          | API or *Active Component | β-Glucan Conc., pg/mg API (Spike Recovery, %) | Lowest Dilution with Acceptable Spike Recovery |
|-----------------------------------|--------------------------|---------------------------------------------|-----------------------------------------------|
| Nano-albumin Paclitaxel           | 5.84 (123)               | 5                                           |
| Liposome Amphotericin             | 21.3 (142)               | 5                                           |
| PEG-liposome Doxorubicin Iron     | 154 (120)                | 50                                          |
| SPIO *Gold                        | 38.5 (70)                | 50                                          |
| Polymer-antibody-drug conjugate Cisplatin | 181,000 (168)        | 50                                          |
| Polysaccharide nanoparticles Paclitaxel | BLOQ (104)              | 500                                         |
| Nanogel                           | 109 (56)                 | 50                                          |
| Polymeric nanoparticle Iodine     | 21.9 (59)                | 50                                          |
| Polymeric Nanoemulsion Propofol   | 117 (111)                | 500                                         |
| Nanocrystal Docetaxel             | 129 (64)                 | 50                                          |
| Polymeric nanoparticle miRNA      | 3128 (81)                | 50                                          |
| Polymeric micelle Paclitaxel      | 1179 (62)                | 500                                         |
| PEG-oligo(FdUMP) FdUMP            | 4.5 (93)                 | 5                                           |
| Polymeric micelle Neoantigen      | BLOQ (64)                | 5                                           |
A variety of approaches have been developed by researchers to overcome the test material’s interference with LAL assays for the quantification of endotoxins, should IEC reveal such interference [2,68,81,82]. One of the most straightforward approaches is to increase the dilution of the test sample. However, there are strict rules for diluting test-samples so as not to undermine the validity of the test results [9]. Specifically, in the case of endotoxin, all dilutions should not exceed the so-called maximum valid dilution (MVD) calculated according to the following formula: MVD = (EL × sample concentration)/λ, where EL is the endotoxin limit and lambda (λ) is the assay sensitivity [9]. The EL is specific to each formulation and is calculated according to the formula EL = K/M, where K is the threshold pyrogenic dose (5 EU/kg for all routes of administration except for the intrathecal route, and 0.2 EU/kg for the intrathecal route) and M is the maximum dose administered in a single hour [9]. Unlike endotoxins, the threshold pyrogenic dose of beta-glucans is not established, and it complicates the estimation of the MVD. This remains one of the current limitations in the methodology for beta-glucan detection—the lack of rules for the estimation of a valid dilution range which would allow for increased dilution to overcome nanoparticle interference with the assay. Even though the use of the lowest, non-interfering dilution is desirable, it is not always practical. Studies to understand safe levels of beta-glucans and establish their threshold dose would aid with experimental design and MVD estimation. Such studies would also help to improve current approaches for data interpretation.

4. Data Interpretation

No compendial procedure or criteria are currently available for the estimation of acceptable levels of β-(1-3)-D-glucans in pharmaceutical products. Below, we describe several approaches proposed by ourselves [81] and others [32,48,83,84].

Approach 1 [83]: This is a risk-based approach that is based on the ICHQ3(R6) recommendations for establishing exposure limits to solvent impurities in drug products [85]. It includes a calculation of the permissible daily exposure (PDE) according to the following formula:

\[ \text{PDE} = \frac{\text{NOAEL} \times \text{weight adjustment}}{(F1 \times F2 \times F3 \times F4 \times F5)} \]

where NOAEL is the no-observed-adverse-effect level derived from a toxicity study, F1 is an animal to human conversion factor, F2 is an inter-human variability factor, F3 is a subacute to chronic exposure factor, F4 is the severity of toxicity factor, and F5 is the lowest observed adverse effect level (LOAEL) to NOAEL conversion factor. The values of F1–F5 factors are 5, 10, 10, 2, and 10 for F1, F2, F3, F4, and F5, respectively.

Approach 2 [48,84]: According to this approach, the levels of beta-glucans should remain in the range of endogenous levels. The endogenous level in a healthy individual is less than 60 pg/mL.

Approach 3 [83]: This is a case-by-case approach that considers both PDE and endogenous levels. This approach considers individual characteristics of the product, such as format (IgG, IgE, fusion protein, etc.), origin (human or non-human), and immune-modulatory mechanism of action, and indication, the immunological status of the patient population, route, and frequency of administration.

Approach 4 [81]: This approach estimates the dose of beta-glucans that would be injected with each dose of nanomaterial and converts it to the beta-glucan quantity per milliliter of blood. It is based on several assumptions: (a) an average adult weight is 70 kg; (b) the blood volume of such an adult is 5.6 L (or 8% of the bodyweight); and (c) the entire injected dose stays in the circulation. The estimated amount of beta-glucans per one milliliter of blood is next compared to the limit (70 pg/mL) used in the clinical diagnostic Fungitell assay where beta-glucan levels are indicative of fungal infection. For example, if the level of beta-glucan is 100 pg/mL of a nanoformulation containing 1 mg/mL of API and the API dose is 1 mg/kg, then the beta-glucan dose is 100 pg/kg; 100 pg × 70 kg = 7000 pg of beta-glucan per 5600 mL of blood. After conversion to the amount per milliliter of blood, the result is 1.25 pg/mL, which is less than 70 pg/mL. Therefore, this would be considered within normal levels of beta-glucans present in the blood from dietary sources.

Approach 5 [32]: This approach estimates that a single dose of 500 ng of beta-glucans results in a plasma concentration of ~100 pg/mL. The same reference indicates that this level is acceptable by the UK Medicines and Healthcare Products Regulatory Agency.
5. Conclusions and Future Directions

Increasing interest in the quantification of beta-glucans in pharmaceutical products is justified by the growing scientific evidence of the inherent immunomodulatory properties of these molecules. While a variety of methods for detection and quantification of beta-glucans are available, there is an urgent need to validate these methods and establish compendial procedures for their application to analyze the quality of nanotechnology-based drug products and vaccines. Lessons learned from the analysis of endotoxin contamination of nanomaterials could guide future research to fulfill this need. Understanding the threshold doses of beta-glucans, estimating the MVD, establishing orthogonal methodologies for verification of test results obtained using LAL-based assays, and approaches for data interpretation are among essential focus areas for future research in this field.

Funding: The study was supported in its entirety by federal funds from the National Cancer Institute, National Institutes of Health, under contract HHSN261200800001E and 75N91019D00024. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

Acknowledgments: We are grateful to Avidea Technologies, Bio-Synectics, Inc., CoD Therapeutics, Nanoprobes, Proteogenomics Research Institute, Siva Therapeutics, ZY Therapeutics, Inc., Raag Airan (Stanford University), William Gmeiner (Wake Forest School of Medicine), Jordan Green (Johns Hopkins University), and John McDonald (Georgia Tech Research Corporation) for providing their nanomaterials for characterization at the NCL. We are also thankful to Melina Richardson, Allen Kane, and Joseph Meyer for help with figure preparation.

Conflicts of Interest: The authors declare no conflicts of interest.

References
1. Haile, L.A.; Puig, M.; Kelley-Baker, L.; Verthelyi, D. Detection of innate immune response modulating impurities in therapeutic proteins. PLoS ONE 2015, 10, e0125078.
2. Dobrovolskaia, M.A.; McNeil, S.E. Endotoxin and Nanomaterials. In Immunological Properties of Engineered Nanomaterials; Dobrovolskaia, M.A.; McNeil, S.E., Eds.; World Scientific Publishing Ltd: Singapore, 2016; Volume 1, pp 143–186.
3. Das, A.P.; Kumar, P.S.; Swain, S. Recent advances in biosensor based endotoxin detection. Biosens. Bioelectron. 2014, 51, 62–75.
4. Dullah, E.C.; Ongkudon, C.M. Current trends in endotoxin detection and analysis of endotoxin-protein interactions. Crit. Rev. Biotechnol. 2017, 37, 251–261.
5. Reich, J.; Lang, P.; Grallert, H.; Motschmann, H. Masking of endotoxin in surfactant samples: Effects on Limulus-based detection systems. Biologicals 2016, 44, 417–422.
6. Sharma, S.K. Endotoxin detection and elimination in biotechnology. Biotechnol. Appl. Biochem. 1986, 8, 5–22.
7. Su, W.; Ding, X. Methods of Endotoxin Detection. J. Lab. Autom. 2015, 20, 354–364.
8. US FDA. Guidance for Industry: Pyrogen and Endotoxins Testing: Questions and Answers; US FDA: Montgomery, MD, USA, 2012.
9. US Pharmacopoeia, Bacterial Endotoxins; US Pharmacopoeia: Washington, WA, USA, 2017.
10. International Standards Organization ISO 29701:2010. Nanotechnologies—Endotoxin Test on Nanomaterial Samples for in vitro Systems—Limulus Amebocyte Lysate (LAL) Test; 2010. Available Online: https://www.iso.org/obp/ui/#iso:std:iso:29701:ed-1:v1:en, (Accessed on date 23 July 2020)
11. Kuriakose, A.; Chirumle, N.; Nair, P. Immunogenicity of Biotherapeutics: Causes and Association with Post translational Modifications. J. Immunol. Res. 2016, 2016, 1298473.
12. Fisher, A.C.; Lee, S.L.; Harris, D.P.; Buhse, L.; Kozlowski, S.; Yu, L.; Kopcha, M.; Woodcock, J. Advancing pharmaceutical quality: An overview of science and research in the U.S. FDA’s Office of Pharmaceutical Quality. Int. J. Pharm. 2016, 515, 390–402.
13. US FDA. Considerations in Demonstrating Interchangeability with A Reference Product; US FDA: Montgomery, MD, USA, 2019.
14. Han, B.; Baruah, K.; Nguyen, D.V.; Williams, D.L.; Devriendt, B.; Cox, E.; Bossier, P. Beta-glucan’s varying structure characteristics modulate survival and immune-related genes expression from Vibrio harveyi-infected Artemia franciscana in gnotobiotic conditions. Fish Shellfish Immunol. 2020, 102, 307–315.
15. Odabasi, Z.; Mattiuzzi, G.; Estey, E.; Kantarjian, H.; Saeki, F.; Ridge, R.J.; Ketchum, P.A.; Finkelman, M.A.; Rex, J.H.; Ostrosky-Zeichner, L. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: Validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. *Clin. Infect. Dis.* 2004, 39, 199–205.

16. Zeković, D.B.; Kwiatkowski, S.; Vrvić, M.M.; Jakovljević, D.; Moran, C.A. Natural and modified (1→3)-beta-D-glucans in health promotion and disease alleviation. *Crit. Rev. Biotechnol.* 2005, 25, 205–230.

17. Zimmerman, J.W.; Lindermuth, J.; Fish, P.A.; Palace, G.P.; Stevenson, T.T.; DeMong, D.E. A novel carbohydrate-glycosphingolipid interaction between a beta-(1-3)-glucan immunomodulator, PGG-glucan, and lactosylceramide of human leukocytes. *J. Biol. Chem.* 1998, 273, 22014–22020.

18. Barsanti, L.; Passarelli, V.; Evangelista, V.; Frassanito, A.M.; Gualtieri, P. Chemistry, physico-chemistry and applications linked to biological activities of β-glucans. *Nat. Prod. Rep.* 2011, 28, 457–466.

19. Garcia-Rubio, R.; de Oliveira, H.C.; Rivera, J.; Trevijano-Contador, N. The Fungal Cell Wall: Candida, Cryptococcus, and Aspergillus Species. *Front. Microbiol.* 2019, 10, 2993.

20. Nous, I.; Doekes, G.; Thorne, P.S.; Heederik, D.J.; Wouters, I.M. Comparison of the potency of a variety of β-glucans to induce cytokine production in human whole blood. *Innate Immun.* 2013, 19, 10–19.

21. Akhapkina, I.G.; Antropova, A.B.; Akhmatov, E.A.; Zheltikova, T.M. Effects of the Linear Fragments of Beta-(1→3)-Glucans on Cytokine Production in vitro. *Biochemistry (Mosc)* 2018, 83, 1002–1006.

22. Mourits, V.P.; Arts, R.J.W.; Novakovic, B.; Matzaraki, V.; de Bree, L.C.J.; Koeken, V.; Moorlag, S.; van Puffelen, J.H.; Groh, L.; van der Heijden, C.; et al. The role of Toll-like receptor 10 in modulation of trained immunity. *Immunology* 2020, 159, 289–297.

23. Rubin-Bejerano, I.; Abejón, C.; Magnelli, P.; Grisafi, P.; Fink, G.R. Phagocytosis by human neutrophils is stimulated by a unique fungal cell wall component. *Cell Host Microbe* 2007, 2, 55–67.

24. Sonck, E.; Stuyven, E.; Goddeeris, B.; Cox, E. The effect of beta-glucans on porcine leukocytes. *Vet. Immunol. Immunopathol.* 2010, 135, 199–207.

25. Higashi, T.; Hashimoto, K.; Takagi, R.; Mizuno, Y.; Okazaki, Y.; Tanaka, Y.; Matsushita, S. Curdlan induces DC-mediated Th17 polarization via Jagged1 activation in human dendritic cells. *Allergol. Int.* 2010, 59, 161–166.

26. Baram, L.; Cohen-Kedar, S.; Spektor, L.; Elad, H.; Guzner-Gur, H.; Dotan, I. Differential stimulation of peripheral blood mononuclear cells in Crohn’s disease by fungal glucans. *J. Gastroenterol. Hepatol.* 2014, 29, 1976–1984.

27. Huang, H.; Ostroff, G.R.; Lee, C.K.; Specht, C.A.; Levitz, S.M. Robust stimulation of humoral and cellular immune responses following vaccination with antigen-loaded beta-glucan particles. *mBio* 2010, 1, e00164-10.

28. Ara, Y.; Saito, T.; Takagi, T.; Hagiwara, E.; Miyagi, Y.; Sugiyama, M.; Kawamoto, S.; Ishii, N.; Yoshida, T.; Hanashi, D.; et al. Zymosan enhances the immune response to DNA vaccine for human immunodeficiency virus type-1 through the activation of complement system. *Immunology* 2001, 103, 98–105.

29. Bonløkke, J.H.; Stridh, G.; Sigsgaard, T.; Kjaergaard, S.K.; Löfstedt, H.; Andersson, K.; Bonefeld-Jørgensen, E.C.; Jayatissa, M.N.; Bodin, L.; Juto, J.E.; et al. Upper-airway inflammation in relation to dust spiked with aldehydes or glucan. *Scand. J. Work Environ. Health* 2006, 32, 374–382.

30. Jawan, A.; Nemikaitė-Čienienė, A.; Bratchikov, M.; Grigaliukas, S.; Grigas, F.; Jonauskienė, I.; Zabulytė, D.; Mauricas, M. β-Glucan from Saccharomyces cerevisiae Induces IFN-γ Production In Vivo in BALB/c Mice. *In Vivo* 2015, 29, 359–363.

31. Johnson, E.; Forland, D.T.; Saetre, L.; Bernardshaw, S.V.; Lyberg, T.; Hetland, G. Effect of an extract based on the medicinal mushroom Agaricus blazei murrill on release of cytokines, chemokines and leukocyte growth factors in human blood ex vivo and in vivo. *Scand. J. Immunol.* 2009, 69, 242–250.

32. Barton, C.; Vigor, K.; Scott, R.; Jones, P.; Lentfer, H.; Bax, H.J.; Josephs, D.H.; Karagiannis, S.N.; Spicer, J.F. Beta-glucan contamination of pharmaceutical products: How much should we accept? *Cancer immunol. Immunother.* CII 2016, 65, 1289–1301.

33. Ławniczek-Walczyk, A.; Górny, R.L. Endotoxins and β-glucans as markers of microbiological contamination—characteristics, detection, and environmental exposure. *Ann. Agric. Environ. Med.* 2010, 17, 193–208.

34. Liss, B.; Cornely, O.A.; Hoffmann, D.; Dimitriou, V.; Wisplinghoff, H. I,3-β-D-Glucan contamination of common antimicrobials. *J. Antimicrob. Chemother.* 2016, 71, 913–915.
35. Chan, G.C.; Chan, W.K.; Sze, D.M. The effects of beta-glucan on human immune and cancer cells. *J. Hematol. Oncol.* 2009, 2, 25.

36. Luther, K.; Torosantucci, A.; Brakhage, A.A.; Heesemann, J.; Ebel, F. Phagocytosis of Aspergillus fumigatus conidia by murine macrophages involves recognition by the dectin-1 beta-glucan receptor and Toll-like receptor 2. *Cell. Microbiol.* 2007, 9, 368–381.

37. Meier, A.; Kirschning, C.J.; Nikolaus, T.; Wagner, H.; Heesemann, J.; Ebel, F. Toll-like receptor (TLR) 2 and TLR4 are essential for Aspergillus-induced activation of murine macrophages. *Cell. Microbiol.* 2003, 5, 561–570.

38. Brown, G.D. Dectin-1: A signalling non-TLR pattern-recognition receptor. *Nat. Rev. Immunol.* 2006, 6, 33–43.

39. Brown, G.D.; Herre, J.; Williams, D.L.; Willment, J.A.; Marshall, A.S.; Gordon, S. Dectin-1 mediates the biological effects of beta-glucans. *J. Exp. Med.* 2003, 197, 1119–1124.

40. Steele, C.; Rapaka, R.R.; Metz, A.; Pop, S.M.; Williams, D.L.; Gordon, S.; Kolls, J.K.; Brown, G.D. The beta-glucan receptor dectin-1 recognizes specific morphologies of Aspergillus fumigatus. *PLoS Pathog.* 2005, 1, e42.

41. Li, X.; Zhang, X.; Pang, L.; Yao, L.; Shang, Z.; Pan, Y. Agaricus bisporus-derived β-glucan enter macrophages and adipocytes by CD36 receptor. *Nat. Prod. Res.* 2019, 1–4. doi:10.1080/14786419.2018.1556654.

42. Rice, P.J.; Kelley, J.L.; Kogan, G.; Ensley, H.E.; Kalbfeisch, J.H.; Browder, I.W.; Williams, D.L. Human monocyte scavenger receptors are pattern recognition receptors for (1–3)-beta-D-glucans. *J. Leukoc. Biol.* 2002, 72, 140–146.

43. Czop, J.K.; Austen, K.F. Generation of leukotrienes by human monocytes upon stimulation of their beta-glucan receptor during phagocytosis. *Proc. Natl. Acad. Sci. USA* 1985, 82, 2751–2755.

44. Ross, G.D.; Cain, J.A.; Myones, B.L.; Newman, S.L.; Lachmann, P.J. Specificity of membrane complement receptor type three (CR3) for beta-glucans. *Complement* 1987, 4, 61–74.

45. Thornton, B.P.; Větvička, V.; Pitman, M.; Goldman, R.C.; Ross, G.D. Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). *J. Immunol. (Baltimore Md. 1950)* 1996, 156, 1235–1246.

46. De Marco Castro, E.; Calder, P.C.; Roche, H.M. β-1,3/1,6-Glucans and Immunity: State of the Art and Future Directions. *Mol. Nutr. Food Res.* 2020, e1901071. doi:10.1002/mnfr.201901071.

47. Rodgers, L.; Milling, S. Recovery training or over-training? The contribution of TLR10 to monocyte fitness. *Immunology* 2020, 159, 243–244.

48. Associates of Cape Cod, *Fungitell: Product Brochure;* Associates of Cape Cod: East Falmouth, MA, USA, 2017; pp 1–7.

49. Ellis, M.; Al-Ramadi, B.; Finkelman, M.; Hedstrom, U.; Kristensen, J.; Ali-Zadeh, H.; Klingspor, L. Assessment of the clinical utility of serial beta-D-glucan concentrations in patients with persistent neutropenic fever. *J. Med. Microbiol.* 2008, 57 Pt 3, 287–295.

50. Ostrosky-Zeichner, L.; Alexander, B.D.; Kett, D.H.; Vazquez, J.; Pappas, P.G.; Saeki, F.; Ketchum, P.A.; Wingard, J.; Schif, R.; Tamura, H.; et al. Multicenter clinical evaluation of the (1→3)-beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. *Clin. Infect. Dis.* 2005, 41, 654–659.

51. Pazos, C.; Pontón, J.; Del Palacio, A. Contribution of (1→3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: A comparison with serial screening for circulating galactomannan. *J. Clin. Microbiol.* 2005, 43, 299–305.

52. Sima, P.; Richter, J.; Větvička, V. Glucans as New Anticancer Agents. *Anticancer Res.* 2019, 39, 3373–3378.

53. Barthow, C.; Hood, F.; McKinlay, E.; Hilder, J.; Clegborn, C.; Huthwaite, M.; Weatherall, M.; Parry-Strong, A.; Pullon, S.; Gray, B.; et al. Food 4 Health–He Oranga Kai: Assessing the efficacy, acceptability and economic implications of Lactobacillus rhamnosus HN001 and β-glucan to improve glycated haemoglobin, metabolic health, and general well-being in adults with pre-diabetes: Study protocol for a 2 × 2 factorial design, parallel group, placebo-controlled randomized controlled trial, with embedded qualitative study and economic analysis. *Trials* 2019, 20, 464.

54. Bordoni, A.; Boesch, C.; Malpuech-Brugère, C.; Orfila, C.; Tomás-Cobos, L. The role of bioactives in energy metabolism and metabolic syndrome. *Proc. Nutr. Soc.* 2019, 78, 340–350.
55. Bose, N.; Ottoson, N.R.; Qiu, X.; Harrison, B.; Lowe, J.R.; Uhlik, M.T.; Rathmann, B.T.; Kangas, T.O.; Jordan, L.R.; Ertelt, K.E.; et al. Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprine PGG in Healthy Volunteers. J. Immunol. (Baltimore Md. 1950) 2019, 202, 2945–2956.
56. Dicks, L.; Ellinger, S. Effect of the Intake of Oyster Mushrooms (Pleurotus ostreatus) on Cardiometabolic Parameters: A Systematic Review of Clinical Trials. Nutrients 2020, 12, 1134.
57. Rahmani, J.; Miri, A.; Černěvičtí, R.; Thompson, J.; de Souza, N.N.; Sultana, R.; Kord Varkaneh, H.; Mousavi, S.M.; Hekmatdoost, A. Effects of cereal beta-glucan consumption on body weight, body mass index, waist circumference and total energy intake: A meta-analysis of randomized controlled trials. Complement Ther. Med. 2019, 43, 131–139.
58. Rieder, A.; Knutsen, S.H.; Sainz Fernandez, A.; Ballance, S. At a high dose even partially degraded beta-glucan with decreased solubility significantly reduced the glycaemic response to bread. Food Funct. 2019, 10, 1529–1539.
59. Vetvicka, V.; Vannucci, L.; Sima, P.; Richter, J. Beta Glucan: Supplement or Drug? From Laboratory to Clinical Trials. Molecules 2019, 24, 1251.
60. Wolever, T.M.S.; Tosh, S.M.; Spruiil, S.E.; Jenkins, A.L.; Ezatagha, A.; Duss, R.; Johnson, J.; Chu, Y.; Steinert, R.E. Increasing oat β-glucan viscosity in a breakfast meal slows gastric emptying and reduces glycemic and insulinemic responses but has no effect on appetite, food intake, or plasma ghrelin and PYY responses in healthy humans: A randomized, placebo-controlled, crossover trial. Am. J. Clin. Nutr. 2020, 111, 319–328.
61. Gefroh, E.; Hewig, A.; Vedantham, G.; McClure, M.; Krivosheyeva, A.; Lajmi, A.; Lu, Y. Multipronged approach to managing beta-glucan contaminants in the downstream process: Control of raw materials and filtration with charge-modified nylon 6,6 membrane filters. Biotechnol. Prog. 2013, 29, 672–680.
62. US FDA. Guidance for industry Immunogenicity Assessment for Therapeutic Protein Products; US FDA: Montgomery, MD, USA, 2014.
63. Dobrovolskaia, M.A.; McNeil, S.E. Endotoxin and engineered nanomaterials. In Handbook of Immunological Properties of Engineered Nanomaterials; Dobrovolskaia, M.A., McNeil, S.E., Eds.; World Scientific Publishing Ltd: Singapore, 2013.
64. Szebeni, J.; Simberg, D.; González-Fernández, Á.; Barenholz, Y.; Dobrovolskaia, M.A. Roadmap and strategy for overcoming infusion reactions to nanomedicines. Nat. Nanotechnol. 2018, 13, 1100–1108.
65. Gordon, M.; Bihari, B.; Goosby, E.; Gorter, R.; Greco, M.; Guralnik, M.; Mimura, T.; Rudinicki, V.; Wong, R.; Kaneko, Y. A placebo-controlled trial of the immune modulator, lentinan, in HIV-positive patients: A phase I/II trial. J. Med. 1998, 29, 305–330.
66. Wada, T.; Nishide, T.; Hatayama, K.; Chang, S.W.; Tatsuta, M.; Yasutomi, M. [A comparative clinical trial with tegafur plus lentinan treatment at two different doses in advanced cancer]. Gan Kagaku Ryoho 1987, 14, 2509–2512.
67. Roslansky, P.F.; Novitsky, T.J. Sensitivity of Limulus amebocyte lysate (LAL) to LAL-reactive glucans. J. Clin. Microbiol. 1991, 29, 2477–2483.
68. Neun, B.W.; Dobrovolskaia, M.A. Considerations and Some Practical Solutions to Overcome Nanoparticle Interference with LAL Assays and to Avoid Endotoxin Contamination in Nanoformulations. Methods Mol. Biol. 2018, 1682, 23–33.
69. Dobrovolskaia, M.A.; Neun, B.W.; Clogston, J.D.; Ding, H.; Ljubimova, J.; McNeil, S.E. Ambiguities in applying traditional Limulus amebocyte lysate tests to quantify endotoxin in nanoparticle formulations. Nanomedicine 2010, 5, 555–562.
70. Dobrovolskaia, M.A.; Neun, B.W.; Clogston, J.D.; Grossman, J.H.; McNeil, S.E. Choice of method for endotoxin detection depends on nanoformulation. Nanomedicine 2014, 9, 1847–1856.
71. Tran, T.; Beal, S.G. Application of the 1,3-beta-D-Glucan (Fungitell) Assay in the Diagnosis of Invasive Fungal Infections. Arch. Pathol. Lab. Med. 2016, 140, 181–185.
72. Associates of Cape Cod 1,3-beta-D-glucan Detection Reagent Kit. Available online: https://www.acciusa.com/pdfs/accProduct/inserts/Glucatell_Kit.pdf (Accessed on 23 July 2020).
73. Associates of Cape Cod Glucashield: Glucan Inhibiting Buffer. Available online: https://www.acciusa.com/pdfs/accProduct/inserts/Glucashield_13DGlucan_Inhibiting_Buffer.pdf (Accessed on 23 July 2020).
74. Fuji Film β-Glucan Test. Available online: https://www.wako-chemicals.de/en/product/v-glucan-test (Accessed on 23 July 2020).
75. Biovision QuickDetectTM 1-3-β-D-glucan (Human) ELISA Kit. Available online: https://www.biovision.com/documentation/datasheets/E4446.pdf (Accessed on 23 July 2020).
76. Megazyme β-Glucan Assay Kit (Yeast & Mushroom). Available online: https://www.megazyme.com/beta-glucan-assay-kit-yeast-mushroom (Accessed on 23 July 2020).
77. Megazyme Enzymatic Yeast β-Glucan Assay Kit. Available online: https://www.megazyme.com/yeast-beta-glucan-assay-kit (Accessed on 23 July 2020).
78. Megazyme β-Glucan Assay Kit (Mixed Linkage). Available online: https://www.megazyme.com/beta-glucan-assay-kit (Accessed on 23 July 2020).
79. Rahar, S.; Swami, G.; Nagpal, N.; Nagpal, M.A.; Singh, G.S. Preparation, characterization, and biological properties of β-glucans. J. Adv. Pharm. Technol. Res. 2011, 2, 94–103.
80. Charles River Endosafe Nexgen-PTS. Available online: https://www.criver.com/sites/default/files/resource-files/Endosafe-nexgen-PTS-Sheet.pdf (Accessed on 23 July 2020).
81. Neun, B.W.; Dobrovolskaia, M.A. Understanding endotoxin and beta-glucan contamination in nanotechnology-based drug products. In Endotoxin Detection and Control in Pharma, Limulus, and Mammalian Systems; Williams, K.L., Ed.; Springer Nature Switzerland AG: 2019; pp. 481–496. Available online: https://link.springer.com/chapter/10.1007/978-3-030-17148-3_12
82. Neun, B.W.; Dobrovolskaia, M.A. Detection and quantitative evaluation of endotoxin contamination in nanoparticle formulations by LAL-based assays. Methods Mol. Biol. 2011, 697, 121–130.
83. Schubert, C.; Moudgal, C. Parenteral Safety of Beta Glucans. In Proceedings of the Presentation at the PDA Endotoxins Workshop, Washington, DC, USA, 18–19 October 2017.
84. Finkelman, M.A. (1″3)-β-D-Glucan: Pharmaceutical Contaminant and Biological Response Modifier. In American Pharmaceutical Review. Endotoxin Supplement; 2016; pp. 16–19. Available online: https://www.americanpharmaceuticalreview.com/Featured-Articles/190861-1-3-D-Glucan-Pharmaceutical-Contaminant-and-Biological-Response-Modifier/
85. ICH. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, Impurities: Guideline for Residual Solvents q3c(R6); 2016. Available online: https://database.ich.org/sites/default/files/Q3C-R6_Guideline_ErrorCorrection_2019_0410_0.pdf

Sample Availability: Protocol for the assessment of beta-glucans that was used to generate the data summarized in Table 4 along with other protocols for nanoparticle characterization are available for public use at https://ncl.cancer.gov/resources/assay-cascade-protocols.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).